VEGF Inhibitors Disappoint in Adjuvant Renal Cell CarcinomaVEGF Inhibitors Disappoint in Adjuvant Renal Cell Carcinoma

Sorafenib and sunitinib do not prolong disease-free survival in patients with completely resected, locally advanced kidney cancer at high risk for recurrence. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news